承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 孫飄揚先生 中國上海 2025年10月9日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-16 ...

智通财经APP讯，恒瑞医药(01276)发布公告，于2025年10月9日斥资762.67万元回购11万股A股股份。 ...

格隆汇10月9日丨恒瑞医药(01276.HK)发布公告，2025年10月9日耗资人民币762.67万元回购11万股A 股，回购价格每股69.2-69.81元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年10月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 9, with Northeast Electric (00042) leading at a premium of 743.75% [1][2]. AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): 743.75% - Andeli Juice (02218): 235.25% - Zhejiang Shibao (01057): 227.36% [1][2] - The bottom three stocks with the lowest AH premium rates are: - Contemporary Amperex Technology (03750): -16.12% - Heng Rui Medicine (01276): -2.39% - China Merchants Bank (03968): 3.49% [1][2] Deviation Values - The stocks with the highest deviation values are: - Changfei Optical Fiber (06869): 28.93% - Zhejiang Shibao (01057): 12.23% - Red Star Macalline (01528): 11.20% [1][2] - The stocks with the lowest deviation values are: - Northeast Electric (00042): -72.24% - Shanghai Electric (02727): -54.73% - Dazhong Public Utilities (01635): -29.80% [1][2]

Group 1 - The core viewpoint of the article highlights the booming IPO market in Hong Kong, driven by improved market sentiment and favorable policies, with the number of IPO applications in the first nine months of the year reaching 380, more than double that of the same period last year [2] - The total fundraising amount for Hong Kong IPOs in the first nine months is approximately HKD 182.4 billion, a significant year-on-year increase of 227.15%, surpassing the US market and ranking first globally [2] - The participation of A-share companies has been a key factor in the IPO heat, with four out of five "super large" transactions being "A+H" shares, including notable companies like CATL and Hengrui Medicine [2][3] Group 2 - The surge in Hong Kong's IPO market is attributed to four main factors: continuous optimization of listing rules by the Hong Kong Stock Exchange, encouragement for mainland companies to list in Hong Kong, tightening of financing in A-shares, and increased regulatory scrutiny of Chinese concept stocks in the US [3] - A total of 13 A-share companies have listed in Hong Kong over the past year, including major players in the hard technology sector [3] - The Hong Kong Stock Exchange has introduced a fast-track approval policy for qualified A-share companies, facilitating their listing process [3][4] Group 3 - The market is undergoing a significant structural change, with a continuous increase in the "technology" content of IPOs, marking a strategic transformation and value reshaping [5] - By the end of September 2025, nearly 20 biotech companies have successfully listed on the Hong Kong Stock Exchange, with 30 more applications from biotech firms currently being processed [5] - The enthusiasm for biotech IPOs has been reignited, with companies like Silver Lake Pharmaceuticals and Zhonghui Biotech experiencing over 3000 times subscription rates [5] Group 4 - The number of companies in the semiconductor, biomedicine, and software service sectors currently applying for listing exceeds 121, accounting for over 43% of the total applications [8] - The influx of technology companies into the Hong Kong market signifies a major upgrade in the industry structure, moving away from the traditional finance and real estate dominance [8] - The Hang Seng Technology Index has surged over 46% year-to-date, reaching a new high since November 2021 [8] Group 5 - In the first nine months of the year, 57 IPO companies in Hong Kong introduced cornerstone investors, representing about 84% of the total IPOs [10] - The active participation of cornerstone investors has positively impacted stock price stability and market confidence, essential for enhancing Hong Kong's attractiveness as an international financial center [10] - The first-day listing performance has improved significantly, with only 16 out of 68 new stocks experiencing a drop on their debut, resulting in a breakage rate of just 23.5% [11] Group 6 - Several biotech companies have seen their stock prices double on the first day of trading, with notable performers including Silver Lake Pharmaceuticals and Zhonghui Biotech [12] - The market has witnessed a significant increase in investor interest in new shares, with record subscription rates for several IPOs, including a historical high of 7558.4 times for a specific company [12][14] - The performance of new consumer stocks has also been remarkable, with companies like Laopuhuangjin experiencing a staggering increase of over 900% in stock price [17] Group 7 - The unique attractiveness of the Hong Kong market is expected to further enhance, driven by valuation advantages, ongoing institutional reforms, and the vibrancy of new economic sectors [18] - Analysts predict that the current market conditions, including the end of the economic downturn and continuous policy support, will lead to further inflows of capital into the Hong Kong market [19] - The upcoming "Top 100 Hong Kong Stocks" evaluation will focus on identifying outstanding IPO companies that align with current industry trends [20]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2025年10月9日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 258,197,600 | RMB | | 1 RMB | | 258,197,600 | | 2. 股份分類 | 普通股 | 股份類別 | A ...

Core Insights - The Global X China Biotechnology ETF (02820) recorded positive returns in August, driven by globalization themes, domestic policy support, improved corporate earnings, and a favorable macro environment [1] - Significant foreign licensing transactions highlight global recognition of the innovation quality of Chinese companies, with an accelerating trend in the number and upfront payment amounts for such transactions over the past two years [1] - The Chinese biotechnology sector is expected to continue being a strong performer in 2023, with improved investor sentiment towards the healthcare sector due to enhanced earnings and commercialization processes [1] Industry Summary - The Chinese biopharmaceutical industry is being propelled by high-quality technology empowerment and policy support, as emphasized by the Chinese Premier during a recent visit [1] - The National Healthcare Security Administration has released a final list of drugs eligible for negotiation, with domestic biotech companies optimistic about upcoming negotiations becoming more favorable and flexible [1] - Reports indicate that the U.S. government is drafting an executive order to restrict Chinese pharmaceuticals and innovative therapies, but Chinese biotech firms may demonstrate resilience due to their capabilities in conducting global clinical trials [2] Company Analysis - Jiangsu Hengrui Medicine (01276) reported Q2 2025 revenue of 8.6 billion RMB (up 12.5% YoY) and a net profit of 2.6 billion RMB (up 25% YoY), with significant contributions from recent IPOs and licensing agreements [3] - Hengrui's new revenue growth point comes from collaboration income, including a licensing agreement with Merck that generated approximately 1.5 billion RMB [3] - Hengrui's recent licensing agreement with Braveheart Bio includes a $65 million upfront payment and potential milestone payments, indicating a strong pipeline for future licensing income [3] - BeiGene (06160) reported Q2 2025 revenue of $1.3 billion (up 18% QoQ) and a net profit of $94.3 million, exceeding market expectations, driven by strong sales of its product BRUKINSA [4] - BeiGene announced a deal with Royalty Pharma to sell sales-sharing rights for its anti-tumor drug IMDELLTRA outside China for up to $950 million, enhancing its cash reserves for future opportunities [4] - The Global X China Biotechnology ETF (02820) invests in 30 companies primarily engaged in the research, development, manufacturing, and distribution of biopharmaceuticals [4]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 8, with Northeast Electric (00042) leading at a premium of 730.77% and Ningde Times (03750) at the bottom with a premium of -17.12% [1][2]. AH Premium Rate Rankings - The top three stocks by AH premium rate are: - Northeast Electric (00042) with a premium of 730.77% [2] - Andeli Juice (02218) with a premium of 238.57% [2] - Zhejiang Shibao (01057) with a premium of 229.35% [2] - The bottom three stocks by AH premium rate are: - Ningde Times (03750) with a premium of -17.12% [2] - Heng Rui Medicine (01276) with a premium of -5.82% [2] - Chifeng Gold (06693) with a premium of -5.72% [2] Deviation Values - The top three stocks by deviation value are: - Red Star Macalline (01528) with a deviation of 20.62% [1] - Zhejiang Shibao (01057) with a deviation of 15.24% [1] - Junda Co., Ltd. (02865) with a deviation of 12.42% [1] - The bottom three stocks by deviation value are: - Northeast Electric (00042) with a deviation of -86.56% [1] - Dazhong Public Utilities (01635) with a deviation of -43.18% [1] - Shanghai Electric (02727) with a deviation of -41.15% [1]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 6, with Northeast Electric (00042) leading at 815.25% and CATL (03750) at -19.28% [1][2] - It also presents the deviation values for these stocks, indicating significant discrepancies between their A-shares and H-shares [1][2] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) with a premium of 815.25% - Andeli Juice (02218) at 237.07% - Zhejiang Shibao (01057) at 231.95% [1] - The bottom three stocks with the lowest AH premium rates are: - CATL (03750) at -19.28% - Hengrui Medicine (01276) at -7.05% - Zijin Mining (02899) at 3.16% [1] Deviation Value Rankings - The stocks with the highest deviation values are: - Red Star Macalline (01528) at 25.18% - Zhejiang Shibao (01057) at 21.61% - Changfei Optical Fiber (06869) at 19.13% [1] - The stocks with the lowest deviation values are: - Dazhong Public Utilities (01635) at -55.59% - Shanghai Electric (02727) at -41.10% - SMIC (00981) at -27.91% [1][2]